Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 2/20 | 0.48 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.48 |
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.38 |
| ▸ | ALPI | P09923 | 1/20 | 0.38 |
| ▸ | XIAP | P98170 | 1/20 | 0.38 |
| ▸ | GRIA2 | P42262 | 4/20 | 0.36 |
| ▸ | GRIA1 | P42261 | 3/20 | 0.36 |
| ▸ | GRIA3 | P42263 | 3/20 | 0.36 |
| ▸ | GRIA4 | P48058 | 3/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | BLM | P54132 | 2/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Histidine SCHEMBL18047802 | 1.00 | PTGS1 (0.48) | PTGS1SLC7A11SLC7A5CYP3A4CYP1A2 | |
| Histidine SCHEMBL22091426 | 1.00 | PTGS1 (0.48) | PTGS1SLC7A11SLC7A5CYP3A4CYP1A2 | |
| Histidine SCHEMBL27769589 | 1.00 | PTGS1 (0.48) | PTGS1SLC7A11SLC7A5CYP3A4CYP1A2 | |
| Histidine SCHEMBL4452747 | 1.00 | PTGS1 (0.48) | PTGS1SLC7A11SLC7A5CYP3A4CYP1A2 | |
| Histidine SCHEMBL1673287 | 1.00 | PTGS1 (0.48) | PTGS1SLC7A11SLC7A5CYP3A4CYP1A2 | |
| Histidine SCHEMBL28655326 | 0.98 | PTGS1 (0.47) | PTGS1SLC7A11SLC7A5CYP3A4CYP1A2 | |
| Histidine SCHEMBL28511880 | 0.98 | PTGS1 (0.47) | PTGS1SLC7A11SLC7A5CYP3A4CYP1A2 | |
| Histidine SCHEMBL28203991 | 0.98 | PTGS1 (0.47) | PTGS1SLC7A11SLC7A5CYP3A4CYP1A2 | |
| Histidine SCHEMBL1692193 | 0.98 | PTGS1 (0.47) | PTGS1SLC7A11SLC7A5CYP3A4CYP1A2 | |
| Histidine SCHEMBL1257407 | 0.94 | PTGS1 (0.43) | PTGS1SLC7A11SLC7A5CYP3A4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 216 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11484607-B2 | PSMA-targeted NIR dyes and their uses | On Target Laboratories, LLC (US) | 2022-11-01 | — | — | US | claimed |
| CN-114558029-A | Copper cluster, thymine modified hyaluronic acid and poly-copper cluster, and preparation method and application thereof | 武汉广行科学研究有限公司 | 2022-05-31 | — | — | CN | claimed |
| US-20210046194-A1 | PSMA-TARGETED NIR DYES AND THEIR USES | On Target Laboratories, Inc. | 2021-02-18 | — | — | US | claimed |
| CN-109022381-A | Amino acid dehydrogenase mutant and its application | 凯莱英生命科学技术(天津)有限公司 | 2018-12-18 | — | — | CN | claimed |
| EP-3347019-A1 | PSMA-TARGETED NIR DYES AND THEIR USES | On Target Laboratories, LLC (US) | 2018-07-18 | — | — | EP | claimed |
| CN-108135903-A | PSMA-targeted NIR dyes and uses thereof | 目标实验室有限责任公司 | 2018-06-08 | — | — | CN | claimed |
| US-20170319717-A1 | PSMA-TARGETED NIR DYES AND THEIR USES | On Target Laboratories, Inc. | 2017-11-09 | — | — | US | claimed |
| US-9801956-B2 | PSMA-targeted NIR dyes and their uses | On Target Laboratories, LLC (US) | 2017-10-31 | — | — | US | claimed |
| US-20170281801-A1 | PSMA-TARGETED NIR DYES AND THEIR USES | On Target Laboratories, Inc. | 2017-10-05 | — | — | US | claimed |
| WO-2017044584-A1 | PSMA-TARGETED NIR DYES AND THEIR USES | On Target Laboratories, LLC (US) | 2017-03-16 | — | — | WO | claimed |
| US-20170065729-A1 | PSMA-TARGETED NIR DYES AND THEIR USES | On Target Laboratories, Inc. | 2017-03-09 | — | — | US | claimed |
| US-20100267608-A1 | MODIFICATIONS OF CUPREDOXIN DERIVED PEPTIDES AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-10-21 | — | — | US | claimed |
| CN-101600447-A | The trim of cupredoxin derived peptides class and using method thereof | UNIV ILLINOIS (US) | 2009-12-09 | — | — | CN | claimed |
| EP-2061487-A2 | MODIFICATIONS OF CUPREDOXIN DERIVED PEPTIDES AND METHODS OF USE THEREOF | The Board of Trustees of the University of Illinois (US) | 2009-05-27 | — | — | EP | claimed |
| WO-2008033820-A2 | MODIFICATIONS OF CUPREDOXIN DERIVED PEPTIDES AND METHODS OF USE THEREOF | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2008-03-20 | — | — | WO | claimed |
| WO-2003099322-A2 | IL-11 DERIVATIVES AND THERAPEUTIC USES THEREOF | ISIS INNOVATION LIMITED (GB) | 2003-12-04 | — | — | WO | claimed |
| EP-0829206-A1 | Edible micro-emulsion for coating food products and its use for browning and crisping in a microwave | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 1998-03-18 | — | — | EP | claimed |
| EP-0769549-A2 | Enzyme mutants having a low degree of variation of the molecular charge over a pH range | NOVO NORDISK A/S (DK) | 1997-04-23 | — | — | EP | claimed |
| US-5206152-A | Including zinc finger regions of the type involved in DNA binding | ARCH DEVELOPMENT CORPORATION (US) | 1993-04-27 | — | — | US | claimed |
| WO-1992011357-A1 | ENZYME MUTANTS HAVING A LOW DEGREE OF VARIATION OF THE MOLECULAR CHARGE OVER A pH RANGE | NOVO NORDISK A/S (DK) | 1992-07-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210046194-A1 | PSMA-TARGETED NIR DYES AND THEIR USES | KLK3, FOLH1, CD47 | PTGS1 1110/4885SLC7A11 1345/4885SLC7A5 854/4885 |
| US-20170281801-A1 | PSMA-TARGETED NIR DYES AND THEIR USES | KLK3, FOLH1, CD47 | PTGS1 1110/4885SLC7A11 1345/4885SLC7A5 854/4885 |
| US-11484607-B2 | PSMA-targeted NIR dyes and their uses | KLK3, FOLH1, CD47 | PTGS1 1110/4885SLC7A11 1345/4885SLC7A5 854/4885 |
| US-20170065729-A1 | PSMA-TARGETED NIR DYES AND THEIR USES | KLK3, FOLH1, CD47 | PTGS1 1110/4885SLC7A11 1345/4885SLC7A5 854/4885 |
| US-20170319717-A1 | PSMA-TARGETED NIR DYES AND THEIR USES | KLK3, FOLH1, CD47 | PTGS1 1110/4885SLC7A11 1345/4885SLC7A5 854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.